Member Info for HotblackDesiato

We're clearly still in the very early stages of discovery so I think once ReceptorAi gets back to us with their full findings, at that point I'd expect more of a fanfare. For the moment all we can say is something might have potential. A computer model demonstrating how our drug could cross the BBB will get the interest of larger players.

Regards.

Hi Andy - getting older by the day! I'm not over the hill just yet but I want SAR to come up trumps sooner rather than later as I'd like to be a millionaire while I can still fully enjoy it!

In response to Edison's article (link below), SP tweeted on23rd Sept tweet, "Fascinating read from the Edison healthcare team - looking forward to the work in CNS by @Sareumplc being featured soon!"

https://www.edisongroup.com/thematic/the-cns-renaissance-innovations-are-reshaping-neurological-therapies/BM-2199/

So the interview was to specifically look at the CNS side of our compounds, nothing more.

Hi Aber - we couldn't begin the collab with ReceptorAi without having the funds already in place so I'm presuming the recent warrant uptakes have eased the financial strain the work might otherwise have applied to our resources.

I think it's been a very smart move to ensure we own the CNS compounds 100% as SP alludes at 8:50 in the video, royalty stacking isn't attractive when you want to either on-license or sell the whole business.

With 737 being the only part-owned compound, we'll be in a very nice position if someone wants the whole shebang.

Yes, video appears to work now.

https://www.youtube.com/watch?v=52ypedWqm00

At the 5:18 mark, "1801 demonstrates a really clean safety profile" - so, letting the cat out the bag from the extended tox trial?

Sounds like lots of positive news to come by the end of the year.

Hi Num4 - I think there's a widespread YT problem as no videos appear to be available at the moment on any channel.

Nothing showing here yet but I don't know if there's any legal obligation requiring a company to be included -

https://www.lse.co.uk/share-prices/financial-diary.html?selected-date=01-Oct-2025&mode=month

Hi NavM - assuming the BoD hang on until the end of the month for the final results, I'd expect buying to pick up after mid-month. Some encouraging noises from ReceptorAi wouldn't go amiss ahead of the report along with confirmation that TM is still active and not on gardening leave.

Meh, when we finally reach lift-off it'll be straight up and none of this rollercoaster malarky.

Scream if you want to go faster.

The Cairngorms in October are good for landscape photography but not much else! Hope the weather isn't too wet for you.

Hi PCS - it'd be nice to think 737 still has legs and we simply haven't heard anything about it recently as it's part of a larger deal. Everything is dovetailing towards the year end for news on all fronts. There are too many research papers utilising 737 to good effect that I find it hard to imagine no one wants it. If 1801 has a class-leading tox profile and ReceptorAi comes up with something exciting then who knows where we'll be within the next 6mths? The sp might even establish itself over 30p!

A final AGM might actually be on the cards this time round.

Interesting post, Krone. Page 36 in the link below for anyone interested -

https://www.sec.gov/Archives/edgar/data/1290149/000119312522134756/d571460dprem14a.htm

J&J's oral drug icotrokinra looks like taking a chunk of sotyktu's market, "Analysts at Jefferies estimated last month that icotrokinra could bring in peak sales of $7.5 billion in the U.S. across various indications, with another $2.1 billion coming from international sales."

https://www.fiercebiotech.com/biotech/jjs-il-23-drug-defeats-reigning-champ-sotyktu-phase-3-psoriasis-trial

Icontrokinra's further down the road than 1801 but note it only inhibits IL-23 whereas 1801 gives greater coverage than single inhibitors. This means 1801 has the potential for increased efficacy across several autoimmune targets. More targets = more revenue. Ker-ching.

Excellent find, Krone. I hope SP is cracking the whip to ensure JR is banging out the related patents. I think CNS/BBB drugs could be the next big thing.

Last year the final results were posted on 29th Oct. and on the 9th in 2023 so we're looking at maybe anywhere from 2 - 5weeks for the report.

I wouldn't be surprised if punters took a chance with their money elsewhere for a week or so but they might miss the boat if a deal appears out of nowhere or results get published early in the month.

Eh, Warthog, you do know that FOI requests only apply to govt. bodies, not businesses/companies?

Hi Pav - As luck would have it, SP has now replied to my recent e-mail and we should get some form of study update in the final results (due end of next month?). He also reminded me that the BoD have always been clear that they are looking at the end of the year for completion.

Good to know the IR postbox is still being monitored.

Regards.

Hi SOG - I was just wondering, 737 has about 8yrs patent life left but Sierra applied for a number of 'in-combo' patents and that IP should have been handed over to CPF/CRUK - see list below. If I'm correct then even if 737 goes out of patent, companies wouldn't be able to use it in combos due to these other patents (assuming they be granted eventually).

https://patents.justia.com/search?q=sra737

Hi SOG, both Gemcitabine and Cisplatin patents expired some time ago (see below) so that may make life easier for a 737 deal as the buyer/licensee isn't necessarily tied to a single manufacturer/owner. At the last investor presentation SP did hint they hoped to update us 'not too far hence' - hmmm, words coming back to bite him?

Gemcitabine (brand name: Gemzar) is a chemotherapy drug approved by the FDA in 1996 for various cancers, including pancreatic, ovarian, breast, and non-small cell lung cancer. Its core compound patent expired in the US in 2010, following earlier expiration in Europe in 2009 and successful patent challenges that invalidated key manufacturing protections. As a result, gemcitabine has been off-patent for over a decade and is widely available as a generic drug from multiple manufacturers, including Accord Healthcare, Teva Pharmaceuticals, Fresenius Kabi, and others. Generic versions are included in over 30 NDAs and are routinely used in clinical practice due to cost-effectiveness.

Cisplatin (brand name: Platinol) is a platinum-based chemotherapy drug approved by the FDA in 1978 for cancers such as testicular, ovarian, and bladder cancer. Its original patents, issued in the late 1970s, expired in the mid-1990s (around 1996 without extensions). Generic versions have been approved and available since at least May 2000, with widespread market entry by multiple suppliers like Hikma, Bedford Laboratories, and Teva. Today, cisplatin is fully generic, with no active compound patents, and is produced by numerous manufacturers for global use.

For all we know there is a 7am RNS prepped for tomorrow.

I'll be back in profit here at 34p but at 42p the gains will mean I'll also have recouped losses from another share. My ultimate goal is to reach £2.30+ which I think is very possible. The tox results will be a major step but we still have other compounds if the tox isn't quite as good as we hoped. SRA737 must be worth a few quid.

On another note, I contacted IR a couple of days ago and despite getting prompt replies to my two previous e-mails, it's radio silence for now. I hope SP is deep in talks and too busy to reply!